Deze keuzehulp is gebaseerd op de richtlijn Diabetes mellitus type 2 (versie 2021) en de richtlijn Cardiovasculair risicomanagement (versie 2019) van het Nederlands Huisartsen Genootschap (NHG).
Gegevens over de bijwerkingen van medicijnen komen uit het Farmacotherapeutisch Kompas, bezocht op 1 t/m 5 juli 2022.
Ook zijn de volgende bronnen gebruikt:
- Guerci B, Chanan N, Kaur S, et al. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Ther 2019;10:437-449. Hier te vinden
- Denicolo S, Perco P, Thöni S, Mayer G. Non-adherence to antidiabetic and cardiovascular drugs in type 2 diabetes mellitus and its association with renal and cardiovascular outcomes: A narrative review. J Diabetes Compl 2021;35:107931. Hier te vinden
- Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018;391:541-551. Hier te vinden
- Nederlandse Diabetes Federatie (NDF). Voedingsrichtlijn Diabetes 2020 (versie 1.0). Hier te vinden
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45:2753-2786. Hier te vinden
- DiNicolantonio JJ, O’Keefe JH. Low-grade metabolic acidosis as a driver of insulin resistance. Open Heart 2021;8:e001788. Hier te vinden
- Nederlandse ZorgAutoriteit (NZA). Hoe is de vergoeding van de GLI geregeld? Website bezocht op 15 september 2022. Hier te vinden
- Shaw KA, Gennat HC, O’Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Datab Syst Rev 2006;4:CD003817. Hier te vinden
- The Look AHEAD Research Group. The Liij AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity 2006;14:737-752. Hier te vinden
- Wing RR, Look AHEAD Research Group. Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes: findings from the Look AHEAD randomized trial. Obesity 2021;29:1246-1258. Hier te vinden
- Cai H, Li G, Zhang P, et al. Effect of exercise on the quality of life in type 2 diabetes mellitus: a systematic review. Qual Life Res 2017;26;515-530. Hier te vinden
- Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203. Hier te vinden
- Grenet G, Ribault S, Nguyen GB, et al. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis. PLoS ONE 2019;14:e0217701. Hier te vinden
- Ding Y, Liu Y, Qu Y, et al. Efficacy and safety of combination therapy with vildagliptin and metformin vs metformin monotherapy for type 2 diabetes mellitus therapy: a meta-analysis. Eur Rev Med Pharmacol Sci 2022;26:2802-2817. Hier te vinden
- Lee AJ. Metformin in noninsulin-dependent diabetes mellitus. Pharmacother 1996;16:327-351. Hier te vinden
- Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia 2013;56:973-984. Hier te vinden
- Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-1258.e22. Hier te vinden
- Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 2019;150:8-16. Hier te vinden
- Qin J, Song L. Glucagon like peptide 1 (GLP 1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta analysis of double blind, randomized, placebo controlled clinical trials. BMC Endocrine Dis 2022;22:125. Hier te vinden
- Yoshiji S, Minamino H, Tanake D, et al. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: a meta analysis and meta-regression analysis. Diabetes Obes Metab 2022;24:1029-1037. Hier te vinden
- Giugliano D, Scappaticcio L, Longo M, et al. GLP 1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta analysis of eight CVOTs. Cardiovasc Diabetol 2021;20:189. Hier te vinden
- Peterson GE, Pollom RD. Liraglutide in clinical practice: dosing, safety and efficacy. Int J Clin Pract 2010;167:35-43. Hier te vinden
- Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016;18:783-794. Hier te vinden
- Padda IS, Mahtani AU, Parmar M. Sodium-glucose transport protein 2 (SGLT2) inhibitors. Versie 6 januari 2022. Hier te vinden
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853. Hier te vinden